PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer.
BRCA and poly-ADP ribose polymerase (PARP) regulate pathways of DNA repair. Due to the accumulation of mutations introduced by error-prone DNA repair, breast and ovarian cancers develop in the setting of BRCA deficiency. A series of recent clinical trials has tested the use of PARP inhibition as a therapeutic strategy to target BRCA-deficient tumors.
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute 10 Center Drive - Room 12N226, Bethesda, MD 20892-1906 USA.
Christina M
CM
Annunziata
Susan E
SE
Bates